Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs glucocorticoid maintenance therapy in adult minimal-change nephrotic syndrome
ChiCTR2200065822Phase 4Recruiting
- Sponsor
- PLA Army Specialty Medical Center
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in nephrosis (2 arms), sponsored by PLA Army Specialty Medical Center. Primary endpoints: Urine protein and Serum albumin. Started Dec 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on ChiCTR2200065822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065822.